Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"WHO International Clinical Trials Registry Platform"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Diabetes+Mellitus%22&type=Subject&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22
/vufind/Search/Results?lookfor=%22Diabetes+Mellitus%22&type=Subject&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22
Search /vufind/Search2/Results?lookfor=%22Diabetes+Mellitus%22&type=Subject&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22
PubPharm (21.564)
1
An MR-scan study of Liraglutide on cardiac function and cardiac blood flow in patients with type 2 diabetes and impaired filling of the heart. : Influence of liraglutide on diastolic cardiac function and myocardial perfusion as determined by magnetic resonance imaging in patients with type 2 diabetes: a double-blind randomized parallel-group trial
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
Comparative effects of Nebivolol and Carvedilol on orthostatic hypotension in hypertensive patients with type 2 diabetes mellitus (DIANECA) - DIANECA : Comparative effects of Nebivolol and Carvedilol on orthostatic hypotension in hypertensive patients with type 2 diabetes mellitus (DIANECA) - DIANECA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
Efficacy of once weekly exenatide long acting release and once daily insulin glargine in patients with Type 2 diabetes treated with metformin alone or in combination with sulphonylurea. - GWBR : Efficacy of once weekly exenatide long acting release and once daily insulin glargine in patients with Type 2 diabetes treated with metformin alone or in combination with sulphonylurea. - GWBR
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
A study to test whether different doses of BI 456906 are effective in treating adults with type 2 diabetes : A Phase II, randomized, parallel group, dose-finding study ofsubcutaneously administered BI 456906 for 16 weeks, comparedwith placebo and open-label semaglutide in patients with type 2diabetes mellitus.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
Effect of Suliqua® (iGlarLixi) on glycemic targets by using continuous glucose monitoring in participants uncontrolled on basal insulin : Suliqua® (iGlarLixi) in Participants uncontrolled on basal insulin to Evaluate the change of time in target Range By using Continuous Glucose Monitoring - SUPERB-CGM
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes Mellitus - GMAJ : A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes Mellitus - GMAJ
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
The Effect of Jardiance on Cardiac and Kidney Metabolism in Persons with Type 2 Diabetes : The Effect of Empagliflozin on Cardiac and Kidney Metabolism in Persons with Type 2 Diabetes
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
8
A trial to compare how much Dasiglucagon and GlucaGen® activates the immune system after injection under the skin in patients with Type 1Diabetes : A phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon And GlucaGen® Administered Subcutaneously in Patients with Type 1 Diabetes Mellitus (T1DM)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
9
Effect of Empagliflozin on Systemic Vascular Resistance and Cardiac Output in Patients with Type 2 Diabetes : Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients with Type 2 Diabetes - EMPA Hemodynamics
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
10
A research study to compare insulin 287 once a week to insulin glargine (100 units/mL) once a day in people with type 2 diabetes. : An investigational trial comparing the efficacy and safety of once weekly NNC0148-0287 C (insulin 287) versus once daily insulin glargine, both in combination with metformin, with or without DPP-4 inhibitors, in insulin naïve subjects with type 2 diabetes mellitus
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[2157]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Medienart
21.564
Aufsätze
21.564
E-Artikel
21.564
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
21.564
610
18.944
Study Type: Interventional
10.308
Recruitment Status: Not yet recruiting
5.176
Recruitment Status: Completed
3.588
Phase: Phase 3
2.990
Recruitment Status: Recruiting
2.270
Study Type: Observational
1.324
Phase: Phase 2
1.286
Phase: Phase 4
1.210
Recruitment Status: Complete: follow-up complete
1.006
Medical Condition: Health Condition 1: E119- Ty...
908
Recruitment Status: Authorised-recruitment may ...
580
Medical Condition: Type 2 diabetes mellitus
528
Phase: Phase 2/Phase 3
382
Medical Condition: type 2 diabetes mellitus
350
Medical Condition: Type 2 Diabetes Mellitus
258
Phase: Phase 1
228
Medical Condition: Diabetes mellitus
226
Medical Condition: diabetes mellitus
216
Recruitment Status: Complete: follow-up continuing
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
11.834
2020-
9.730
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
21.106
Englisch
266
Unbestimmt
120
Spanisch
24
Niederländisch
12
Französisch
10
Deutsch
6
Italienisch
6
Portugiesisch
6
Schwedisch
4
Dänisch
2
Afrikaans
2
Tschechisch
Alle anzeigen ...
weniger ...
Haven't found what you're looking for?
Wird geladen...